Evidence map›Paper›PMID 24424052›Full record

ArticleEndocrinology2014

Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation.

Huansheng Dong, Hu Huang, Xinxu Yun, Do-sung Kim, Yinan Yue, Hongju Wu, Alton Sutter, Kenneth D Chavin, Leo E Otterbein, David B Adams and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients.European journal of drug metabolism and pharmacokinetics · 2018
    Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Inflammation, Dopaminergic Brain and Bilirubin.International journal of molecular sciences · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Huansheng DongDepartment of Surgery (H.D., X.Y., D.-s.K., A.S., K.D.C., D.B.A., H.Wa.), Medical University of South Carolina, Charleston, South Carolina 29425; Departments of Endocrinology, Diabetes, and Metabolism (H.H., Y.-B.K.) and Surgery (Y.Y., L.E.O.), Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215; Department of Medicine (H.Wu), Section of Endocrinology, Tulane University, New Orleans, Louisiana 70112 and Department of Kinesiology and Physiology (H.H.), East Carolina University, Greenville, North Carolina 27858.
Hu Huang
Xinxu Yun
Do-sung Kim
Yinan Yue
Hongju Wu
Alton Sutter
Kenneth D Chavin
Leo E Otterbein
David B Adams
Young-Bum Kim
Hongjun Wang
Medical University of South Carolina · USBeth Israel Deaconess Medical Center · USHarvard University · USTulane University · US

Funding

SOUTH CAROLINA CLINICAL & TRANSLATIONAL RESEARCH INSTITUTE (SCTR)UL1RR029882 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2009 to 2011
$10.1M
ROCK1 Signaling in Glucose MetabolismR01DK083567 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KIM, YOUNG-BUM · 2010 to 2018
$3.4M
A Novel Approach to Prevent Surgical Diabetes in Chronic Pancreatitis PatientsR21DK097544 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2014 to 2015
$411k
Novel Strategies to Increase Insulin Independence after Islet AutotransplantationR03EB015744 · NIBIB · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WANG, HONGJUN · 2013 to 2014
$147k
NCRR NIH HHS UL1 RR029882NCRR NIH HHS UL1RR029882NIBIB NIH HHS EB015744NIBIB NIH HHS R03 EB015744NIDDK NIH HHS 1R01DK083567NIDDK NIH HHS DK097544NIDDK NIH HHS R01 DK083567NIDDK NIH HHS R21 DK097544
6 · The paper itself

Abstract

Obesity-induced endoplasmic reticulum (ER) stress causes chronic inflammation in adipose tissue and steatosis in the liver, and eventually leads to insulin resistance and type 2 diabetes (T2D). The goal of this study was to understand the mechanisms by which administration of bilirubin, a powerful antioxidant, reduces hyperglycemia and ameliorates obesity in leptin-receptor-deficient (db/db) and diet-induced obese (DIO) mouse models. db/db or DIO mice were injected with bilirubin or vehicle ip. Blood glucose and body weight were measured. Activation of insulin-signaling pathways, expression of inflammatory cytokines, and ER stress markers were measured in skeletal muscle, adipose tissue, and liver of mice. Bilirubin administration significantly reduced hyperglycemia and increased insulin sensitivity in db/db mice. Bilirubin treatment increased protein kinase B (PKB/Akt) phosphorylation in skeletal muscle and suppressed expression of ER stress markers, including the 78-kDa glucose-regulated protein (GRP78), CCAAT/enhancer-binding protein (C/EBP) homologous protein, X box binding protein (XBP-1), and activating transcription factor 4 in db/db mice. In DIO mice, bilirubin treatment significantly reduced body weight and increased insulin sensitivity. Moreover, bilirubin suppressed macrophage infiltration and proinflammatory cytokine expression, including TNF-α, IL-1β, and monocyte chemoattractant protein-1, in adipose tissue. In liver and adipose tissue of DIO mice, bilirubin ameliorated hepatic steatosis and reduced expression of GRP78 and C/EBP homologous protein. These results demonstrate that bilirubin administration improves hyperglycemia and obesity by increasing insulin sensitivity in both genetically engineered and DIO mice models. Bilirubin or bilirubin-increasing drugs might be useful as an insulin sensitizer for the treatment of obesity-induced insulin resistance and type 2 diabetes based on its profound anti-ER stress and antiinflammatory properties.

Indexed as

Endoplasmic Reticulum StressInsulin ResistanceAnimalsBilirubinBody WeightEndoplasmic ReticulumEndoplasmic Reticulum Chaperone BiPGlucose Tolerance TestHeme Oxygenase-1InflammationInsulinLeptinLiverMaleMembrane ProteinsMiceBilirubinEndoplasmic Reticulum Chaperone BiPHeme Oxygenase-1Hmox1 protein, mouseHspa5 protein, mouseInsulinLeptinMembrane ProteinsReceptors, Leptin

Identifiers

PMID24424052
PMCPMC3929745
OpenAlexW2122025820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.